glucagon-like-peptide-1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

1. 43/100

   Potential Role of Glucagon-like Peptide-1 Receptor Agonists in the Treatment of Cognitive Decline and Dementia in Diabetes Mellitus

   ✓ Peer-reviewed alzhub usefulness score 43 out of 100. International journal of molecular sciences · 2023-07-11 · Drug development

   Dementia is a permanent illness characterized by mental instability, memory loss, and cognitive decline.

   • Treatments
   • Brain Biology
   • Risk Factors
2. 41/100

   Resveratrol Modulates the Gut-Brain Axis: Focus on Glucagon-Like Peptide-1, 5-HT, and Gut Microbiota

   ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Frontiers in aging neuroscience · 2020-11-24 · Drug development

   Resveratrol is a natural polyphenol that has anti-aging and anti-inflammatory properties against stress condition.

   • Risk Factors
3. 38/100

   Sitagliptin protects the cognition function of the Alzheimer's disease mice through activating glucagon-like peptide-1 and BDNF-TrkB signalings

   ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Neuroscience letters · 2018-12-28 · Drug development

   Sitagliptin treatment effectively protected the cognition function of the AD mice by regulating synaptic plasticity, at least partially, through activating GLP-1 and BDNF-TrkB signalings.

   • Brain Biology
   • Treatments
4. 38/100

   Glucagon-like peptide-1 mediates effects of oral galactose in streptozotocin-induced rat model of sporadic Alzheimer's disease

   ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Neuropharmacology · 2018-02-28 · Drug development

   Insulin resistance and metabolic dysfunction in the brain are considered to be the pathophysiological core of sporadic Alzheimer's disease (sAD).

   • Treatments
5. 40/100

   Blast traumatic brain injury-induced cognitive deficits are attenuated by preinjury or postinjury treatment with the glucagon-like peptide-1 receptor agonist, exendin-4

   ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association · 2015-08-29 · Drug development

   The present data suggest shared pathologic processes between concussive and B-TBI, with end points amenable to beneficial therapeutic manipulation by Ex-4.

   • Treatments
   • Risk Factors
6. 36/100

   Glucagon-like peptide-1 regulates mitochondrial biogenesis and tau phosphorylation against advanced glycation end product-induced neuronal insult: Studies in vivo and in vitro

   ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Neuroscience · 2015-05-15 · Drug development

   Our previous study has proved that glucagon-like peptide-1 (GLP-1), which is developed to treat type 2 diabetes, has a significant effect on neuroprotection against advanced glycation end product (AGE)-induced neuronal insult in vitro models of diabetes-related Alzheimer's disease (AD).

   • Brain Biology
7. 36/100

   Encapsulated native and glucagon-like peptide-1 transfected human mesenchymal stem cells in a transgenic mouse model of Alzheimer's disease

   ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Neuroscience letters · 2011-04-12 · Drug development

   Encapsulated human mesenchymal stem cells(MSC) are studied in a double transgenic mouse model of Alzheimer's disease (AD) after intraventricular implantation at 3 months of age.

   • Brain Biology

All topic tags with their study counts